Vijayaraj K Palanirajan

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7721704/publications.pdf

Version: 2024-02-01

49 papers	1,727 citations	471509 17 h-index	276875 41 g-index
52 all docs	52 docs citations	52 times ranked	2245 citing authors

#	Article	IF	Citations
1	A New Approach for Î²-cyclodextrin Conjugated Drug Delivery System in Cancer Therapy. Current Drug Delivery, 2022, 19, 266-300.	1.6	11
2	Fabrication and Evaluation of Transdermal Microneedles for a Recombinant Human Keratinocyte Growth Factor. Turkish Journal of Pharmaceutical Sciences, 2021, 18, 96-103.	1.4	11
3	In silico-based Approach to Investigate the Ability of PEGylated Rapamycin to Inhibit Galectin-3. Current Drug Discovery Technologies, 2021, 18, 451-456.	1.2	1
4	Mucoadhesive Low Molecular Chitosan Complexes to Protect rHuKGF from Proteolysis: In-vitro Characterization and FHs 74 Int Cell Proliferation Studies. Current Pharmaceutical Biotechnology, 2021, 22, 969-982.	1.6	5
5	Revolution in the Synthesis, Physio-chemical and Biological Characterization of Gold Nanoplatform. Current Pharmaceutical Design, 2021, 27, 2482-2504.	1.9	7
6	Regulatory mechanisms of heme regulatory protein BACH1: a potential therapeutic target for cancer. Medical Oncology, 2021, 38, 122.	2.5	10
7	Preparation of Chitosan Particles as a Delivery System for Tetrahydrocurcumin: Î²-cyclodextrin Inclusive Compound for Colorectal Carcinoma. Current Drug Therapy, 2021, 16, 430-438.	0.3	4
8	Cyclodextrin inclusion complex inhibits circulating galectin-3 and FGF-7 and affects the reproductive integrity and mobility of Caco-2 cells. Scientific Reports, 2020, 10, 17468.	3.3	5
9	Enhanced gastrointestinal survivability of recombinant Lactococcus lactis using a double coated mucoadhesive film approach. PLoS ONE, 2019, 14, e0219912.	2.5	10
10	Molecular Modeling-_Based Delivery System Enhances Everolimus-Induced Apoptosis in Caco-2 Cells. ACS Omega, 2019, 4, 8767-8777.	3.5	10
11	Rabbit as an Animal Model for Pharmacokinetics Studies of Enteric Capsule Contains Recombinant Human Keratinocyte Growth Factor Loaded Chitosan Nanoparticles. Current Clinical Pharmacology, 2019, 14, 132-140.	0.6	4
12	Preparation and In vitro Evaluation of Enteric Coated Oral Vancomycin Hydrochloride Sustained Release Formulation with Mucoadhesive Properties. American Journal of Advanced Drug Delivery, 2018, 06, .	0.2	2
13	Detection of Formation of Recombinant Human Keratinocyte Growth Factor Loaded Chitosan Nanoparticles Based on its Optical Properties. Current Nanoscience, 2018, 14, 127-135.	1.2	5
14	Optimization and In-vitro Evaluation of Coating Process for Film-Coated Tablets. International Journal of Food Engineering, 2017, 13, .	1.5	0
15	Formulation of Rifampicin Loaded PEGylated 5.0G EDA-PAMAM Dendrimers as Effective Long-Duration Release Drug Carriers. Current Drug Therapy, 2017, 12, .	0.3	8
16	Antiepileptic properties of novel 2-(substituted benzylidene)-7-(4-chlorophenyl)-5-(furan-2-yl)-2 H -thiazolo[3,2 -a]pyrimidin-3(7 H)-one derivatives. Journal of Saudi Chemical Society, 2016, 20, S1-S6.	5.2	1
17	Formulation and evaluation of voriconazole ophthalmic solid lipid nanoparticles in situ gel. International Journal of Pharmaceutical Investigation, 2016, 6, 56.	0.3	34
18	Polyethylene glycolated PAMAM dendrimers-Efavirenz conjugates. International Journal of Pharmaceutical Investigation, 2014, 4, 15.	0.3	20

#	Article	IF	Citations
19	Microwave-assisted synthesis, characterization and biological activity of novel pyrazole derivatives. Journal of Saudi Chemical Society, 2014, 18, 1015-1021.	5.2	34
20	Designing and In-Vitro Characterization of Micelle Forming Amphiphilic PEGylated Rapamycin Nanocarriers for the Treatment of Gastric Cancer. Current Drug Delivery, 2014, 11, 613-620.	1.6	6
21	RP-HPLC method for the determination of acipimox in human plasma. Journal of Pharmacy Research, 2013, 7, 117-120.	0.4	0
22	RP-HPLC determination of vildagliptin in pure andÂin tablet formulation. Journal of Pharmacy Research, 2013, 7, 113-116.	0.4	17
23	PEGylated dendritic nanoarchitechture improves mean survival time of BDF1 mice bearing myelogenous k -562 leukemia. Journal of Acute Disease, 2013, 2, 327-329.	0.3	2
24	Antiepileptic Activity of Novel 2-(substituted benzylidene)-7-(4-) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 547 Td (fluorophenyl)-5-(furan-2-y and Discovery, 2013, 10, 204-211.	0.7	1
25	Antiepileptic Activity of Novel 2-(substituted benzylidene)-7-(4-) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 507 Td (fluorophenyl)- and Discovery, 2013, 10, 204-211.	0.7	1
26	Recent Advances in Physical Approaches for Transdermal Penetration Enhancement. Current Drug Therapy, 2012, 7, 184-197.	0.3	4
27	Design, synthesis, antinociceptive, and anti-inflammatory properties of thiazolopyrimidine derivatives. Toxicological and Environmental Chemistry, 2012, 94, 1247-1258.	1.2	10
28	Synthesis and structure-activity relationship study of 2-(substituted) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 387 Td (benzylidene)-7-(4-flu anticancer agents. Drug Discoveries and Therapeutics, 2012, , .	1.5	8
29	Synthesis and anticonvulsant activity of 6,7,8,9-tetra hydro-5H-5-(2â€²-hydroxy phenyl)-2-(4â€²-substituted) Tj ETQq1 1 0.784314 rg Environmental Chemistry, 2011, 93, 643-655.	1.2	5
30	Synthesis and cAMP-dependent phosphodiesterase inhibition of novel thiazoloquinazoline derivatives. Acta Pharmaceutica, 2011, 61, 103-13.	2.0	3
31	Synthesis, characterization, and antihyperglycemic activity of novel oxazolidine derivatives. Archives of Pharmacal Research, 2011, 34, 887-891.	6.3	4
32	Dendrimers as therapeutic agents: a systematic review. Journal of Pharmacy and Pharmacology, 2010, 61, 989-1003.	2.4	148
33	Synthesis of Novel 6,7,8,9-Tetrahydro-5H-5-hydroxyphenyl-2-benzylidine-3-substituted Hydrazino Thiazolo (2,3-b) Quinazoline as Potent Antinociceptive and Anti-inflammatory Agents. Bulletin of the Korean Chemical Society, 2010, 31, 3265-3271.	1.9	5
34	UV Spectrophotometric Estimation of Acipimox inBulk and Capsule Dosage Form. E-Journal of Chemistry, 2009, 6, 1117-1120.	0.5	1
35	UV Spectrophotometric Method for Determination of Cinitapride in Pure and its Solid Dosage Form. E-Journal of Chemistry, 2009, 6, S21-S24.	0.5	3
36	PEGylated PPI dendritic architectures for sustained delivery of H2 receptor antagonist. European Journal of Medicinal Chemistry, 2009, 44, 1155-1166.	5.5	87

#	Article	IF	Citations
37	Dendrimers in Oncology: An Expanding Horizon. Chemical Reviews, 2009, 109, 49-87.	47.7	446
38	Dendrimers as therapeutic agents: a systematic review. Journal of Pharmacy and Pharmacology, 2009, 61, 989-1003.	2.4	68
39	Novel PEGylated PPI Dendritic Nanostructures for Sustained Delivery of Anti-Inflammatory Agent. Current Nanoscience, 2008, 4, 267-277.	1.2	33
40	Dendrimeric nanoarchitectures mediated transdermal and oral delivery of bioactives. Indian Journal of Pharmaceutical Sciences, 2008, 70, 431.	1.0	32
41	Pharmaceutical and Biomedical Potential of PEGylated Dendrimers. Current Pharmaceutical Design, 2007, 13, 415-429.	1.9	119
42	PEGylated Dendritic Architecture for Development of a Prolonged Drug Delivery System for an Antitubercular Drug. Current Drug Delivery, 2007, 4, 11-19.	1.6	64
43	Suppression of agglomeration of ciprofloxacin-loaded human serum albumin nanoparticles. AAPS PharmSciTech, 2007, 8, E118-E123.	3.3	28
44	Ultrathin multilayer capsules in drug delivery. Indian Journal of Pharmaceutical Sciences, 2007, 69, 479.	1.0	1
45	Intracellular macrophage uptake of rifampicin loaded mannosylated dendrimers. Journal of Drug Targeting, 2006, 14, 546-556.	4.4	194
46	Dendrosome-based gene delivery. Journal of Experimental Nanoscience, 2006, 1, 235-248.	2.4	30
47	Functional Polymeric Nanoparticles: An Efficient and Promising Tool for Active Delivery of Bioactives. Critical Reviews in Therapeutic Drug Carrier Systems, 2006, 23, 259-318.	2.2	140
48	Evaluation of Antidiarrheal Potential ofEmblica officinalis.. Pharmaceutical Biology, 2005, 43, 373-377.	2.9	30
49	New Generation Peptide-Based Vaccine Prototype. , 0, , .		2